Korro Bio, Inc.
KRRO· Nasdaq
KRROKorro Bio, Inc.
Filed Mar 26, 2020 · 10-K · 86 days after period end · 0001564590-20-012977
| Metric | Q4 2019 | Q4 2018 |
|---|---|---|
| Revenue | $4.71M | — |
| Net Income | -$5.49M | -$5.45M |
| EPS Diluted | -$0.19 | -$3.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Mar 26, 2020 · 86 d after period end
